While NovoCure Ltd has overperformed by 3.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVCR fell by -41.24%, with highs and lows ranging from $34.13 to $14.17, whereas the simple moving average fell by -13.19% in the last 200 days.
On July 08, 2025, Ladenburg Thalmann started tracking NovoCure Ltd (NASDAQ: NVCR) recommending Buy. A report published by Evercore ISI on December 02, 2024, Upgraded its rating to ‘Outperform’ for NVCR. H.C. Wainwright also Upgraded NVCR shares as ‘Buy’, setting a target price of $30 on the company’s shares in a report dated October 16, 2024. JP Morgan Initiated an Neutral rating on November 20, 2023, and assigned a price target of $15. H.C. Wainwright August 28, 2023d its ‘Buy’ rating to ‘Neutral’ for NVCR, as published in its report on August 28, 2023. Piper Sandler’s report from August 08, 2023 suggests a price prediction of $45 for NVCR shares, giving the stock a ‘Overweight’ rating. SVB Securities also rated the stock as ‘Outperform’.
Analysis of NovoCure Ltd (NVCR)
Further, the quarter-over-quarter increase in sales is 11.91%, showing a positive trend in the upcoming months.
To gain a thorough understanding of NovoCure Ltd’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -45.52% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.41, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and NVCR is recording an average volume of 1.24M. On a monthly basis, the volatility of the stock is set at 5.13%, whereas on a weekly basis, it is put at 4.60%, with a loss of -1.63% over the past seven days. Furthermore, long-term investors anticipate a median target price of $31.88, showing growth from the present price of $17.51, which can serve as yet another indication of whether NVCR is worth investing in or should be passed over.
How Do You Analyze NovoCure Ltd Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.39%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 77.15% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NVCR shares are owned by institutional investors to the tune of 77.15% at present.
